×
About 1,090 results

ALLMedicine™ Angioimmunoblastic T-cell Lymphoma Center

Research & Reviews  335 results

Darinaparsin in Patients with Relapsed or Refractory Peripheral T-Cell Lymphoma: Result...
https://doi.org/10.1182/bloodadvances.2022008615
Blood Advances; Kim WS, Fukuhara N et. al.

Jan 21st, 2023 - Darinaparsin is a novel organic arsenical compound of dimethylated arsenic conjugated to glutathione, with antitumor activity and a mechanism of action markedly different from other available agents. This phase II, nonrandomized, single-arm, open-...

Anti-ICOS Monoclonal Antibody MEDI-570 in Treating Patients With Relapsed or Refractory Peripheral T-cell Lymphoma Follicular Variant or Angioimmunoblastic T-cell Lymphoma
https://clinicaltrials.gov/ct2/show/NCT02520791

Jan 19th, 2023 - PRIMARY OBJECTIVE: I. To determine the safety, maximum tolerated dose and recommended phase II dose (RP2D) of anti-ICOS monoclonal antibody MEDI-570 (MEDI-570) in patients with refractory/relapsed peripheral T-cell lymphoma-not otherwise specified...

T Cells Expressing a Fully-Human Anti-CD30 Chimeric Antigen Receptor for Treating CD30-Expressing Lymphomas
https://clinicaltrials.gov/ct2/show/NCT03049449

Jan 18th, 2023 - Background: Improved treatments for a variety of treatment-resistant, TNFRSF8 (CD30)-expressing malignancies including Hodgkin lymphoma, anaplastic large cell lymphoma, and other CD30- expressing lymphomas are needed. T cells can be genetically mo...

Efficacy and Safety of Oral Azacitidine Compared to Investigator's Choice Therapy in Patients With Relapsed or Refractory AITL
https://clinicaltrials.gov/ct2/show/NCT03593018

Dec 7th, 2022 - Compared to B-cell Non-Hodgin Lymphoma (NHL), Angioimmunoblastic T-cell Lymphoma (AITL) is more resistant to conventional chemotherapy and is generally associated with an inferior outcome. In case of relapsed of refractory disease, survival durati...

Combination Chemotherapy and Lenalidomide in Treating Patients With Newly Diagnosed Stage II-IV Peripheral T-cell Non-Hodgkin's Lymphoma
https://clinicaltrials.gov/ct2/show/NCT02561273

Nov 8th, 2022 - PRIMARY OBJECTIVES: I. To assess the safety and efficacy of lenalidomide in combination with standard induction therapy (CHOEP- cyclophosphamide, doxorubicin [doxorubicin hydrochloride], etoposide, vincristine [vincristine sulfate] and prednisone)...

see more →

Guidelines  1 results

T-Cell Lymphomas, Version 2.2022, NCCN Clinical Practice Guidelines in Oncology.
https://doi.org/10.6004/jnccn.2022.0015
Journal of the National Comprehensive Cancer Network : JN... Horwitz SM, Ansell S et. al.

Mar 12th, 2022 - Peripheral T-cell lymphomas (PTCLs) are a heterogeneous group of lymphoproliferative disorders arising from mature T cells, accounting for about 10% of non-Hodgkin lymphomas. PTCL-not otherwise specified is the most common subtype, followed by ang...

see more →

Drugs  1 results see all →

Clinicaltrials.gov  28 results

Anti-ICOS Monoclonal Antibody MEDI-570 in Treating Patients With Relapsed or Refractory Peripheral T-cell Lymphoma Follicular Variant or Angioimmunoblastic T-cell Lymphoma
https://clinicaltrials.gov/ct2/show/NCT02520791

Jan 19th, 2023 - PRIMARY OBJECTIVE: I. To determine the safety, maximum tolerated dose and recommended phase II dose (RP2D) of anti-ICOS monoclonal antibody MEDI-570 (MEDI-570) in patients with refractory/relapsed peripheral T-cell lymphoma-not otherwise specified...

T Cells Expressing a Fully-Human Anti-CD30 Chimeric Antigen Receptor for Treating CD30-Expressing Lymphomas
https://clinicaltrials.gov/ct2/show/NCT03049449

Jan 18th, 2023 - Background: Improved treatments for a variety of treatment-resistant, TNFRSF8 (CD30)-expressing malignancies including Hodgkin lymphoma, anaplastic large cell lymphoma, and other CD30- expressing lymphomas are needed. T cells can be genetically mo...

Efficacy and Safety of Oral Azacitidine Compared to Investigator's Choice Therapy in Patients With Relapsed or Refractory AITL
https://clinicaltrials.gov/ct2/show/NCT03593018

Dec 7th, 2022 - Compared to B-cell Non-Hodgin Lymphoma (NHL), Angioimmunoblastic T-cell Lymphoma (AITL) is more resistant to conventional chemotherapy and is generally associated with an inferior outcome. In case of relapsed of refractory disease, survival durati...

Combination Chemotherapy and Lenalidomide in Treating Patients With Newly Diagnosed Stage II-IV Peripheral T-cell Non-Hodgkin's Lymphoma
https://clinicaltrials.gov/ct2/show/NCT02561273

Nov 8th, 2022 - PRIMARY OBJECTIVES: I. To assess the safety and efficacy of lenalidomide in combination with standard induction therapy (CHOEP- cyclophosphamide, doxorubicin [doxorubicin hydrochloride], etoposide, vincristine [vincristine sulfate] and prednisone)...

Phase 1 Trial of ST-001 nanoFenretinide in Relapsed/Refractory T-cell Non-Hodgkin Lymphoma
https://clinicaltrials.gov/ct2/show/NCT04234048

Oct 26th, 2022 - Fenretinide has been shown to be a relatively safe and effective anticancer therapy; however, dose limiting toxicities due to the excipients used in previous formulations has impeded its therapeutic utility. The product formulation in the current ...

see more →

News  71 results

FDA Grants Fast Track Designation to MT-101 for CD5+ Relapsed/Refractory PTCL
https://www.onclive.com/view/fda-grants-fast-track-designation-to-mt-101-for-cd5-relapsed-refractory-ptcl

Nov 21st, 2022 - The FDA has granted a fast track designation to MT-101 for use as a potential therapeutic option in patients with relapsed or refractory, CD5-positive peripheral T-cell lymphoma (PTCL), according to an announcement from Myeloid Therapeutics, Inc.1...

European Commission Grants Orphan Drug Designation to Nana-val for Peripheral T-cell Lymphoma
https://www.onclive.com/view/european-commission-grants-orphan-drug-designation-to-nana-val-for-peripheral-t-cell-lymphoma

Sep 27th, 2022 - The European Commission has granted an orphan drug designation to nanatinostat and valganciclovir (Nana-val) for use as a potential therapeutic option in patients with peripheral T-cell lymphoma (PTCL), according to an announcement from Viracta Th...

Tolinapant Displays Encouraging Activity and Safety in Relapsed/Refractory PTCL/CTCL
https://www.onclive.com/view/tolinapant-displays-encouraging-activity-and-safety-in-relapsed-refractory-ptcl-ctcl

Aug 31st, 2022 - Single-agent tolinapant (ASTX660) generated promising response rates with a manageable safety profile in patients with relapsed/refractory peripheral T-cell lymphoma (PTCL) and cutaneous T-cell lymphoma (CTCL), according to data from the phase 2 A...

Dr. Mehta-Shah on the Variations of the CHOP Regimen in PTCL
https://www.onclive.com/view/dr-mehta-shah-on-the-variations-of-the-chop-regimen-in-ptcl

Jul 20th, 2022 - Neha Mehta-Shah, MD, MSCI, associate professor, Department of Medicine, Oncology Division, Medical Oncology, Washington University School of Medicine in St. Louis, and medical oncologist, Siteman Cancer Center, discusses variations of CHOP-based c...

CHOP-Based Combinations Represent Evolving Standard of Care in Frontline Treatment of PTCL
https://www.onclive.com/view/chop-based-combinations-represent-evolving-standard-of-care-in-frontline-treatment-of-ptcl

Jul 19th, 2022 - CHOP-based chemotherapy (cyclophosphamide, doxorubicin, vincristine, and prednisone) remains the standard of care in the frontline setting for patients with peripheral T-cell lymphoma (PTCL). Although the addition of agents including etoposide and...

see more →